The jury is in: no benefit of escalated prophylactic anticoagulation in patients with COVID-19

Questions surrounding the efficacy and safety of escalated thromboprophylaxis regimens in critically ill COVID-19 patients may have been answered as another large trial shows the strategy does not have an advantage over standard care in reducing deaths or venous or arterial thrombosis. COVID-19 expert guidance supporting the use of intermediate-dose prophylactic anticoagulation early on in ...

Already a member?

Login to keep reading.

© 2021 the limbic